Latest Imatinib Stories
EAST SETAUKTET, N.Y., Feb. 25, 2015 /PRNewswire/ -- Lixte Biotechnology Holdings Inc.
- Fewer patients on Tasigna vs. Gleevec had their leukemia progress to advanced stage, a key goal of treatment in CML and important clinical benefit (1) EAST HANOVER, N.J., Dec.
LONDON, Nov. 27, 2014 /PRNewswire/ -- INTRODUCTIONTargeted therapeutics is fast emerging as the key focus area in biopharmaceutical industry.
DUBAI, UAE, November 24, 2014 /PRNewswire/ -- Five American winners will receive the highly prestigious "Sheikh Hamdan Bin Rashid Al Maktoum Awards for Medical Sciences",
Significant Opportunity Exists for New Therapies to Treat GIST, Particularly those for Treating Unresectable and/or Metastatic Disease in Later-Line Settings BURLINGTON, Mass., Aug.
LONDON, August 11, 2014 /PRNewswire/ -- Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces that the first patients have been dosed in the United
Peer-Reviewed Case Study from Fox Chase Cancer Center Demonstrates Value of Company's Unique Approach to Precision Medicine to Uncover Critical Treatment Insights IRVING, Texas, Aug.
The Upcoming Entry of New Generation TKIs will Challenge the Established Position of CML Treatments in Brazil and Mexico, According to Findings from Decision Resources Group BURLINGTON, Mass.,
High Cost and High Expectations for Clinical Benefits are Major Market Access Hurdles Facing New CML Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., June 2,
Robust Value Dossiers and Smart Uptake Strategies are Vital to Secure Optimal Market Access in Europe, According to Findings from Decision Resources Group BURLINGTON, Mass., May 27, 2014 /PRNewswire/
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.